Document is current
Any future updates will be listed below
-
Authors
Zani, Fabio
Blagih, Julianna
Gruber, Tim
Buck, Michael D. http://orcid.org/0000-0002-9611-1199
Jones, Nicholas http://orcid.org/0000-0003-4846-5117
Hennequart, Marc
Newell, Clare L. http://orcid.org/0000-0003-1809-2305
Pilley, Steven E. http://orcid.org/0000-0001-9670-3314
Soro-Barrio, Pablo
Kelly, Gavin http://orcid.org/0000-0001-7219-560X
Legrave, Nathalie M.
Cheung, Eric C.
Gilmore, Ian S. http://orcid.org/0000-0002-0981-2318
Gould, Alex P. http://orcid.org/0000-0002-6875-6985
Garcia-Caceres, Cristina
Vousden, Karen H. http://orcid.org/0000-0002-7365-1766
- License Information
-
More Information
Article History
Received: 15 September 2021
Accepted: 6 February 2023
First Online: 15 March 2023
Competing interests
: K.H.V. is on the board of directors and shareholder of Bristol Myers Squibb and on the scientific advisory board (with stock options) of PMV Pharma, RAZE Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the scientific advisory board of Ludwig Cancer and a co-founder and consultant of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of patent application WO/2017/144877. J.B. is funded by a fellowship from the Kuok Family, who did not influence any aspects of the research. The other authors declare no competing interests.
